Table 1. Samples tested under code.
Code | Sample | Anti-HCV plasma screening | Anti-HCV RIBA II | Anti-E1* | Anti-E2* | HCV RNA | Virus inactivation | IgG, % |
---|---|---|---|---|---|---|---|---|
1 | Control IGIV | EIA-2 neg | Neg | Neg | Neg | Neg | Yes | 5 |
2 | HCIGIV | EIA-2 pos | Pos | Pos | Pos | Neg | Yes | 5 |
3 | HCIGIV | EIA-1 pos | Pos | Pos | Pos | Pos | No | 5 |
4 | HCIGIV | EIA-1 pos | Pos | ND | ND | Neg | Yes | 5 |
5 | Human albumin | EIA-2 neg | N/A | N/A | N/A | Neg | Yes | (5% prot) |
6 | Plasma pool | EIA-1 pos | Pos | Pos | Pos | Pos | No | 1† |
7 | Plasma pool | EIA-2 neg | Neg | Neg | Neg | Neg | No | 1† |
8 | Gammagard | EIA-2 neg | Neg | Neg | Neg | Neg | No | 10 |
9 | Gammagard | EIA-2 neg | Neg | Neg | Neg | Pos | No | 10 |
10 | Gammagard | EIA-2 neg | Neg | Neg | Neg | Pos | No | 10 |
11 | Gammagard | EIA-2 neg | Neg | Neg | Neg | Pos | No | 10 |
12 | Gammagard | EIA-2 neg | Neg | Neg | Neg | Pos | No | 10 |
13 | Gammagard | Unscreened | Pos | Pos | Pos | Neg | No | 10 |
14 | Gammagard | Unscreened | Pos | Pos | Pos | Neg | No | 10 |
15 | Gammagard | Unscreened | Pos | ND | ND | Neg | No | 10 |
16 | Gammagard | Unscreened | Pos | ND | ND | Neg | No | 10 |
17 | IGIV | EIA-3 neg | ND | ND | ND | Neg | Yes | 10 |
18 | Gammagard | Unscreened | Pos | ND | ND | Neg | No | 10 |
19 | Gammagard | Unscreened | Pos | ND | ND | Neg | No | 10 |
pos, positive; neg, negative; ND, not determined; N/A, not applicable.
In-house EIA procedures for anti-E1 and anti-E2 (see Materials and Methods for details)
Assumed value